Foghorn Therapeutics Analyst Ratings
Foghorn Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/13/2023 | 85.76% | Morgan Stanley | $10 → $6 | Maintains | Equal-Weight |
08/07/2023 | 519.2% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
07/06/2023 | 209.6% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
06/29/2023 | 488.24% | Goldman Sachs | $21 → $19 | Maintains | Buy |
06/28/2023 | 519.2% | HC Wainwright & Co. | $20 → $20 | Reiterates | Buy → Buy |
06/08/2023 | 519.2% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
05/09/2023 | 333.44% | Wedbush | $15 → $14 | Maintains | Outperform |
05/09/2023 | 519.2% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
04/25/2023 | 488.24% | BMO Capital | $20 → $19 | Maintains | Outperform |
04/25/2023 | 364.4% | Wedbush | $20 → $15 | Maintains | Outperform |
03/28/2023 | 209.6% | B of A Securities | → $10 | Initiates Coverage On | → Buy |
03/10/2023 | 673.99% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
03/10/2023 | 519.2% | Wedbush | $25 → $20 | Maintains | Outperform |
01/05/2023 | 519.2% | BMO Capital | → $20 | Initiates Coverage On | → Outperform |
11/21/2022 | 333.44% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
08/24/2022 | 364.4% | Morgan Stanley | $25 → $15 | Downgrades | Overweight → Equal-Weight |
08/10/2022 | 673.99% | HC Wainwright & Co. | $18 → $25 | Maintains | Buy |
05/24/2022 | 550.15% | Goldman Sachs | $30 → $21 | Maintains | Buy |
05/23/2022 | 673.99% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
05/20/2022 | 457.28% | HC Wainwright & Co. | $25 → $18 | Maintains | Buy |
12/15/2021 | 704.95% | Morgan Stanley | $23 → $26 | Maintains | Overweight |
11/22/2021 | 673.99% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
03/23/2021 | 612.07% | Morgan Stanley | $24 → $23 | Maintains | Overweight |
11/17/2020 | 643.03% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
11/17/2020 | 643.03% | Morgan Stanley | → $24 | Initiates Coverage On | → Overweight |
11/17/2020 | 735.91% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
11/17/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/13/2023 | 85.76% | 摩根士丹利 | 10 美元 → 6 美元 | 维护 | 重量相等 |
08/07/2023 | 519.2% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
07/06/2023 | 209.6% | 摩根士丹利 | 13 美元 → 10 美元 | 维护 | 重量相等 |
06/29/2023 | 488.24% | 高盛 | 21 美元 → 19 美元 | 维护 | 买 |
06/28/2023 | 519.2% | HC Wainwright & Co. | 20 美元 → 20 美元 | 重申 | 购买 → 购买 |
06/08/2023 | 519.2% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
05/09/2023 | 333.44% | Wedbush | 15 美元 → 14 美元 | 维护 | 跑赢大盘 |
05/09/2023 | 519.2% | HC Wainwright & Co. | 25 美元 → 20 美元 | 维护 | 买 |
2023 年 4 月 25 日 | 488.24% | BMO Capital | 20 美元 → 19 美元 | 维护 | 跑赢大盘 |
2023 年 4 月 25 日 | 364.4% | Wedbush | 20 美元 → 15 美元 | 维护 | 跑赢大盘 |
03/28/2023 | 209.6% | B of A 类证券 | → 10 美元 | 启动覆盖范围开启 | → 购买 |
03/10/2023 | 673.99% | HC Wainwright & Co. | → 25 美元 | 重申 | → 购买 |
03/10/2023 | 519.2% | Wedbush | 25 美元 → 20 美元 | 维护 | 跑赢大盘 |
01/05/2023 | 519.2% | BMO Capital | → 20 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
11/21/2022 | 333.44% | 摩根士丹利 | 15 美元 → 14 美元 | 维护 | 重量相等 |
2022 年 8 月 24 日 | 364.4% | 摩根士丹利 | 25 美元 → 15 美元 | 降级 | 超重 → 重量相等 |
08/10/2022 | 673.99% | HC Wainwright & Co. | 18 美元 → 25 美元 | 维护 | 买 |
2022 年 5 月 24 日 | 550.15% | 高盛 | 30 美元 → 21 美元 | 维护 | 买 |
05/23/2022 | 673.99% | 摩根士丹利 | 26 美元 → 25 美元 | 维护 | 超重 |
05/20/2022 | 457.28% | HC Wainwright & Co. | 25 美元 → 18 美元 | 维护 | 买 |
2021 年 12 月 15 日 | 704.95% | 摩根士丹利 | 23 美元 → 26 美元 | 维护 | 超重 |
11/22/2021 | 673.99% | HC Wainwright & Co. | → 25 美元 | 启动覆盖范围开启 | → 购买 |
03/23/2021 | 612.07% | 摩根士丹利 | 24 美元 → 23 美元 | 维护 | 超重 |
2020 年 11 月 17 日 | 643.03% | Wedbush | → 24 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2020 年 11 月 17 日 | 643.03% | 摩根士丹利 | → 24 美元 | 启动覆盖范围开启 | → 超重 |
2020 年 11 月 17 日 | 735.91% | 高盛 | → 27 美元 | 启动覆盖范围开启 | → 购买 |
2020 年 11 月 17 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics(FHTX)的目标价格是多少?
The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by Morgan Stanley on November 13, 2023. The analyst firm set a price target for $6.00 expecting FHTX to rise to within 12 months (a possible 85.76% upside). 15 analyst firms have reported ratings in the last year.
摩根士丹利于2023年11月13日公布了Foghorn Therapeutics(纳斯达克股票代码:FHTX)的最新目标股价。该分析公司将目标股价定为6.00美元,预计FHTX将在12个月内升至12个月内(可能上涨85.76%)。去年有15家分析公司公布了评级。
What is the most recent analyst rating for Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics(FHTX)的最新分析师评级是多少?
The latest analyst rating for Foghorn Therapeutics (NASDAQ: FHTX) was provided by Morgan Stanley, and Foghorn Therapeutics maintained their equal-weight rating.
摩根士丹利对Foghorn Therapeutics(纳斯达克股票代码:FHTX)的最新分析师评级由摩根士丹利提供,Foghorn Therapeutics维持同等权重评级。
When is the next analyst rating going to be posted or updated for Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics(FHTX)的下一份分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Foghorn Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Foghorn Therapeutics的最新评级是在2023年11月13日公布的,因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Foghorn Therapeutics (FHTX) correct?
分析师对Foghorn Therapeutics(FHTX)的评级是否正确?
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a maintained with a price target of $10.00 to $6.00. The current price Foghorn Therapeutics (FHTX) is trading at is $3.23, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Foghorn Therapeutics(FHTX)评级维持不变,目标股价为10.00美元至6.00美元。Foghorn Therapeutics(FHTX)目前的交易价格为3.23美元,超出了分析师的预期区间。